Reports Q3 revenue $41.271M, consensus $40.46M. “We are pleased with our performance in the quarter, which includes improvement in our emergent trauma category as well as continued strength in scheduled procedures. This performance was driven by stabilization in the hospital operating environment, and improved commercial execution,” stated Karen Zaderej, Axogen’s Chairman, CEO, and President. “We remain focused on executing our strategic initiatives anchored in the strength of our clinical data, innovation, market development, and commercial execution to continue to drive surgeon adoption and growth.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AXGN:
- Axogen, Inc. Reports 2023 Third Quarter Financial Results
- AXGN Earnings this Week: How Will it Perform?
- Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
- Wayfair upgraded, JD.com downgraded: Wall Street’s top analyst calls
- AxoGen initiated with an Outperform at Leerink